'Turning the right screw': targeting the interleukin-6 receptor to reduce unfavourable tissue remodelling after myocardial infarction.
Möllmann
Helge
H
Nef
Holger M
HM
Troidl
Christian
C
D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000494:pharmacology*; D018932:Chemokine CCL2 / Q000378:metabolism; D005355:Fibrosis; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D051379:Mice; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009206:Myocardium / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D020556:Neutrophil Infiltration / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors* / Q000276:immunology; D014463:Ultrasonography; D020257:Ventricular Remodeling / Q000187:drug effects*
D057134:Antibodies, Neutralizing; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D009195:Peroxidase; D020778:Matrix Metalloproteinase 2; C522362:Mmp2 protein, mouse